CAR-T Cell Therapy Resource Center
News & Information for Healthcare Professionals
VIDEO: Genetically Modified T Cells Obliterate Chronic Lymphocytic Leukemia Tumors
Published on August 31, 2011
Researchers at Penn's Abramson Cancer Center have molecularly engineered T-cells from patients with chronic lymphocytic leukemia and achieved an exceptional,...
FDA Approves First Gene Therapy in the United States
August 30, 2017 (HealthDay News)
Kymriah approved for patients up to 25 years of age with refractory or relapsed B-cell precursor ALL
The U.S. Food...
CAR T-Cell Therapy HCP Guide – Further Questions and Ongoing Research
CAR T: Further Questions and Ongoing Research
Scientists and clinicians alike are excited about this new therapy that may offer extended survival to certain patients...
StatPearls Question of the Week – #10
There is some experimental work using chimeric antigen receptor engineered T cells (CAR-T cells) for therapy to target cancer stem cells. What CD receptor...
July 12, 2017 – Novartis CAR-T Cell Therapy One Step Closer to FDA Approval
"The U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee unanimously voted to recommend approval for CTL019, an experimental cancer drug that belongs to...
VIDEO: Dr. Roboz on Challenges With CAR T-cell Therapy in ALL
Published on Aug 4, 2017
Gail Roboz, MD, a professor of Medicine and director of the Clinical and Translational Leukemia Program at Weill Cornell Medicine/NewYork-Presbyterian...
Cell mechanism discovery could lead to ‘fundamental’ change in leukemia treatment
July 31, 2017 (Medical News Today)
A lack of understanding of molecular mechanisms which let cancer cells escape detection from the immune system is...
CAR T-cell therapy for leukemia leads to remissions in clinical trial
July 19, 2017 (Medical News Today)
Following an experimental chimeric antigen receptor (CAR) T-cell immunotherapy, researchers presented that 70 percent of patients with the...
Human antibody bolsters cancer drug performance
July 1, 2017 (Medical News Today)
The cancer drug, rituximab, is not a chemotherapy, but a monoclonal antibody therapy that uses antibodies which stick...
Remission Up With T Cell Therapy for Non-Hodgkin’s Lymphoma
September 8, 2016 (HealthDay News)
Researchers identify treatment characteristics that correlate with therapeutic response, toxicity
Immunotherapy with CD19 chimeric antigen receptor (CAR)-modified T cells in a...
